Immunology and Cancer

免疫学和癌症

基本信息

批准号：
10162524
负责人：
THOMAS F GAJEWSKI
金额：
$ 4.64万
依托单位：
UNIVERSITY OF CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
起止时间：
1997-09-01 至 2023-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10162524
关键词：
Antigen Targeting Back Basic Science Biological Markers Cancer Center Support Grant Cancer Model Cancer Patient Carcinogens Cells Cellular biology Chicago Clinic Clinical Clinical Research Clinical Trials Collaborations Complex Comprehensive Cancer Center Data Development Direct Costs Disease Doctor of Philosophy Environment Extramural Activities Faculty Fostering Funding Genetic Engineering Goals Grant Home Human Immune response Immune system Immunologics Immunologist Immunology Immunotherapeutic agent Immunotherapy Inflammation International Intervention Investigation Investigational Therapies Knowledge Laboratories Leadership Lymphocyte Activation Malignant Neoplasms Medicine Mentors Natural Immunity Oncology Group Pathology Patients Peripheral Phase Physicians Pilot Projects Play Postdoctoral Fellow Pre-Clinical Model Process Property Publications Publishing Radiation Regulation Regulatory Pathway Regulatory T-Lymphocyte Research Research Personnel Resistance Resource Sharing Role STING agonists Scientist Seminal Sister Strategic Planning T-Lymphocyte Testing Training Translating Transplantation Tumor Antigens Tumor Biology Tumor Immunity United States National Institutes of Health Universities anti-PD1 therapy anticancer research base biomarker discovery cancer immunotherapy cancer regression cancer therapy cancer type career clinical application clinical biomarkers community center fundamental research graduate student host microbiota immunoregulation in vivo inhibitor/antagonist insight member mid-career faculty mouse model multidisciplinary next generation novel novel strategies phase 1 testing pre-clinical professor programs recruit success symposium tool tumor tumor immunology tumor microenvironment

项目摘要

ABSTRACT In the past decade, it has become clear that the immune system can be manipulated to induce cancer regression, durable disease stabilization, and long-term survival in a substantial fraction of cancer patients. Building on this success, members of the Immunology and Cancer (IC) Program aim to better understand the interface between the host immune system and a malignant tumor, and to use this knowledge to develop more effective immunotherapies for the treatment of a broad array of cancer types. The central themes of the Program include: 1) basic immunology relevant to the cancer context (including innate immunity, lymphocyte activation, and peripheral inflammation/tolerance regulation); 2) preclinical mouse models of anti-tumor immunity; and 3) human cancer immunology and immunotherapy. Through the pursuit of these themes, IC members have made fundamental discoveries regarding immune regulation and anti-tumor immunity, and in collaboration with clinical colleagues in the Clinical and Experimental Therapeutics (CET) Program, have leveraged many of these concepts for the development of novel immunotherapies that are now being evaluated in the clinic. The Program is co-led by Thomas Gajewski, MD PhD, Professor of Pathology and Medicine, and Peter Savage, PhD, Associate Professor of Pathology. Dr. Gajewski is a physician-scientist and international leader in the field of tumor immunology and the successful implementation of cancer immunotherapy in human patients. Dr. Savage is a recognized leader in the study of regulatory T cell biology and the role of these cells in the regulation of anti-tumor immunity. There are 18 program members from seven Departments. The IC Program has recruited five new faculty since 2013, including Jason Luke, MD, Melody Swartz, PhD, Jun Huang, PhD, Seungmin Hwang, PhD, and James Labelle, MD, PhD. During the last funding period (2013-2016), program members have published 224 cancer-related articles (with 13% intraprogrammatic and 19% interprogrammatic publications). As of January 2017, Program members hold 36 grants, and are supported by $6.6M (direct costs) in NIH extramural funding, including 6 grants and $1.0M (direct costs) from the NCI. Program members are supported by an additional $2.23 M (direct costs) in non- peer-reviewed support, resulting in total support of $8.9 M (direct costs).

抽象的在过去的十年中，很明显可以操纵免疫系统以诱导癌症大量癌症患者的回归，持久的疾病稳定和长期生存。在这一成功的基础上，免疫学和癌症（IC）计划的成员旨在更好地了解宿主免疫系统与恶性肿瘤之间的接口，并利用这些知识来发展更多有效治疗广泛的癌症类型的有效免疫疗法。中央主题程序包括：1）与癌症环境有关的基本免疫学（包括先天免疫，淋巴细胞激活和周围炎症/耐受性调节）； 2）抗肿瘤的临床前小鼠模型免疫; 3）人类癌症免疫学和免疫疗法。通过追求这些主题，IC 成员已经对免疫调节和抗肿瘤免疫做出了基本发现，与临床和实验治疗学（CET）计划的临床同事合作，已有利用许多此类概念用于开发现在正在的新型免疫疗法在诊所进行评估。该计划由病理学教授和医学和彼得·萨维奇（Peter Savage）博士，病理学副教授。 Gajewski博士是医师科学家，肿瘤免疫学领域的国际领导者和成功实施癌症人类患者的免疫疗法。 Savage博士是调节性T细胞生物学研究的公认领导者这些细胞在调节抗肿瘤免疫力中的作用。七个计划成员有18位部门。自2013年以来，IC计划已招募了五个新教师，其中包括Melody的Jason Luke，Melody Swartz，PhD，Jun Huang，PhD，Seungmin Hwang，PhD和医学博士James Labelle博士。在上次资金中期间（2013-2016），计划成员发表了224篇与癌症相关的文章（有13％磁内图和19％的解释性出版物）。截至2017年1月，计划成员持有36 赠款，并得到NIH校外资金的660万美元（直接费用），其中包括6个赠款和100万美元（直接费用）来自NCI。计划成员在非 - 的额外支持2.23 m（直接费用）的支持同行评审的支持，导致总支持$ 8.9 m（直接费用）。